Systemic Immun Inflamation Score Corelation in Postoperative Patients Prognosis

April 18, 2026 updated by: Leman Acun Delen, Malatya Egitim Ve Arastirma Hastanesi

Prognostic Value of Systemic Immun Inflamation Index in Geriatrik Patient Admitted to the ICU After Surgery: A Prospective Observational Study

The Systemic Immuno-Inflammation Index (SII) is a ratio derived from complete blood count parameters (neutrophils, lymphocytes, platelets) and is a non-invasive and easily calculable biomarker. The SIPI effectively reflects both local and systemic inflammatory responses in the human body. It has been used to predict and evaluate the prognosis of various solid tumors such as gastric cancer, non-small cell lung cancer, and colorectal cancer. Furthermore, the SIPI has been shown to have significant prognostic value in cardiovascular and cerebrovascular diseases. In this study, the SIPI will be calculated using laboratory data at the time of admission to the intensive care unit, and the relationship between the obtained values and the 30-day mortality status of the patients will be analyzed.

Study Overview

Status

Not yet recruiting

Conditions

Study Type

Observational

Enrollment (Estimated)

150

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

65 years of age or older postoperative patients

Description

Inclusion Criteria:

  • The patient must be 65 years of age or older (in the geriatric age group),
  • Admitted to the intensive care unit after elective or emergency surgery
  • Have access to complete blood count (hemogram) data (neutrophils, lymphocytes, platelets) during their stay in the intensive care unit
  • Be able to undergo 30-day mortality monitoring from the date of admission to the intensive care unit
  • Have provided informed consent from the patient or their legal representative.

Exclusion Criteria:

  • Patients under 65 years of age
  • Patients admitted to the intensive care unit for non-surgical reasons (e.g., trauma, medical intensive care indications)
  • Patients with deficient neutrophil, lymphocyte, or platelet counts upon admission to the intensive care unit
  • Patients with a history of malignancy, hematological disease, or immunosuppressive therapy
  • Terminally ill palliative patients
  • Patients who refuse informed consent.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Measuring the Systemic Immune-Inflammation Index (SII) in postoperative patients to see the parameter's predictibility of 30-day mortality
Time Frame: Postoperative day 1
In geriatric patients admitted to the intensive care unit after surgery, the Systemic Immune-Inflammation Index (SII) is a significant biomarker for predicting 30-day mortality.
Postoperative day 1

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Malatya Egitim Ve Arastirma Hastanesi

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

June 15, 2026

Primary Completion (Estimated)

July 15, 2026

Study Completion (Estimated)

July 30, 2026

Study Registration Dates

First Submitted

April 9, 2026

First Submitted That Met QC Criteria

April 18, 2026

First Posted (Actual)

April 22, 2026

Study Record Updates

Last Update Posted (Actual)

April 22, 2026

Last Update Submitted That Met QC Criteria

April 18, 2026

Last Verified

January 1, 2026

More Information

Terms related to this study

Other Study ID Numbers

  • MEAH-SII-ICU-2026-01

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Postop Adult ICU Patients

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Malta

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe